

Research update Immunovia: All eyes on securing the launch of PancreaSure

Carlsquare Equity Research has updated its view on Immunovia following the publication of the report for the first quarter of 2025.

Read the full update here.

About Carlsquare

Carlsquare is a global research firm and financial advisor, focusing on M&A, Equity Research and Growth Equity. Carlsquare has 150 employees with deep sector knowledge in all 11 GICS sectors. The senior equity research team has extensive experience about the stock environment and several business sectors. The team produces company research reports, independent valuations and trading notes. The group have offices in Canada, Denmark, France, Germany, Poland, Sweden, United Kingdom and United States. Read more

Contacts

MARKUS AUGUSTSSON Head of Equity Research markus.augustsson@carlsquare.com +46 (0)76 235 03 20

NIKLAS ELMHAMMER Senior Equity Analyst niklas.elmhammer@carlsquare.com +46 (0)70 898 39 59

Attachments

Research update Immunovia: All eyes on securing the launch of PancreaSure